Primary Localized Gastrointestinal Stromal Tumors: Medication Adherence and Prognosis According to Gender

References

• Rubin BP, Heinrich MC, Corless CL. Gastrointestinal stromal tumour. Lancet. 2007;369(9574):1731–1741. doi:10.1016/S0140-6736(07)60780-6
   PubMed Web of Science ®Google Scholar
• Zhang H, Liu Q. Prognostic indicators for gastrointestinal stromal tumors: a review. Transl Oncol. 2020;13(10):100812. doi:10.1016/j.tranon.2020.100812
   PubMed Web of Science ®Google Scholar
• Joensuu H, Vehtari A, Riihimäki J, et al. Risk of recurrence of gastrointestinal stromal tumour after surgery: an analysis of pooled population-based cohorts. Lancet Oncol. 2012;13(3):265–274. doi:10.1016/S1470-2045(11)70299-6
   PubMed Web of Science ®Google Scholar
• Liu X, Lin E, Sun Y, et al. Postoperative adjuvant imatinib therapy-associated nomogram to predict overall survival of gastrointestinal stromal tumor. Front Med. 2022;9:777181. doi:10.3389/fmed.2022.777181
   Web of Science ®Google Scholar
• Sharma AK, Kim TS, Bauer S, Sicklick JK. Gastrointestinal stromal tumor: new insights for a multimodal approach. Surg Oncol Clin N Am. 2022;31(3):431–446. doi:10.1016/j.soc.2022.03.007
   PubMed Web of Science ®Google Scholar
• Hsu KH, Yang TM, Shan YS, Lin PW. Tumor size is a major determinant of recurrence in patients with resectable gastrointestinal stromal tumor. Am J Surg. 2007;194(2):148–152. doi:10.1016/j.amjsurg.2006.10.033
   PubMed Web of Science ®Google Scholar
• Laurent M, Brahmi M, Dufresne A, et al. Adjuvant therapy with imatinib in gastrointestinal stromal tumors (GISTs)-review and perspectives. Transl Gastroenterol Hepatol. 2019;4:24. doi:10.21037/tgh.2019.03.07
   PubMed Web of Science ®Google Scholar
• Tetzlaff ED, Davey MP. Optimizing adherence to adjuvant imatinib in gastrointestinal stromal tumor. J Adv Pract Oncol. 2013;4(4):238–250.
   PubMedGoogle Scholar
• Nilsson B, Bümming P, Meis-Kindblom JM, et al. Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era–a population-based study in western Sweden. Cancer. 2005;103(4):821–829. doi:10.1002/cncr.20862
   PubMed Web of Science ®Google Scholar
• Woodall CE 3rd, Brock GN, Fan J, et al. An evaluation of 2537 gastrointestinal stromal tumors for a proposed clinical staging system. Arch Surg. 2009;144(7):670–678. doi:10.1001/archsurg.2009.108
   PubMedGoogle Scholar
• Miettinen M, Lasota J. Gastrointestinal stromal tumors: pathology and prognosis at different sites. Semin Diagn Pathol. 2006;23(2):70–83. doi:10.1053/j.semdp.2006.09.001
   PubMed Web of Science ®Google Scholar
• Rong J, Chen S, Song C, et al. The prognostic value of gender in gastric gastrointestinal stromal tumors: a propensity score matching analysis. Biol Sex Differ. 2020;11(1):43. doi:10.1186/s13293-020-00321-8
   PubMed Web of Science ®Google Scholar
• Ge XY, Lei LW, Ge F, Jiang X. Analysis of risk factors of gastrointestinal stromal tumors in different age groups based on SEER database. Scand J Gastroenterol. 2019;54(4):480–484. doi:10.1080/00365521.2019.1604798
   PubMed Web of Science ®Google Scholar
• Wang Y, Zhang P, Han Y, et al. Adherence to adjuvant imatinib therapy in patients with gastrointestinal stromal tumor in clinical practice: a cross-sectional study. Chemotherapy. 2019;64(4):197–204. doi:10.1159/000505177
   PubMed Web of Science ®Google Scholar
• Zhang P, Zhang J, Zhang B, et al. 中国胃肠间质瘤患者伊马替尼服药依从性的多中心横断面调查. [Adherence to adjuvant with therapy imatinib in patients with gastrointestinal stromal tumor: a national multi-center cross-sectional study]. Zhonghua Wei Chang Wai Ke Za Zhi. 2021;24(9):775–782. Chinese. doi:10.3760/cma.j.cn.441530-20210426-00174
   PubMedGoogle Scholar
• Joensuu H, Eriksson M, Sundby Hall K, et al. One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial. JAMA. 2012;307(12):1265–1272. doi:10.1001/jama.2012.347
   PubMed Web of Science ®Google Scholar
• Azam F, Latif MF, Farooq A, et al. Performance status assessment by using ECOG (Eastern Cooperative Oncology Group) score for cancer patients by oncology healthcare professionals. Case Rep Oncol. 2019;12(3):728–736. doi:10.1159/000503095
   PubMed Web of Science ®Google Scholar
• Breccia M, Efficace F, Alimena G. Adherence to treatment is a complex and multifaceted issue that can substantially alter the outcome of chronic myeloid leukemia patients treated with tyrosine kinase inhibitors. Leuk Res. 2012;36(7):804–805. doi:10.1016/j.leukres.2012.02.032
   PubMed Web of Science ®Google Scholar
• Hall AE, Paul C, Bryant J, et al. To adhere or not to adhere: rates and reasons of medication adherence in hematological cancer patients. Crit Rev Oncol Hematol. 2016;97:247–262. doi:10.1016/j.critrevonc.2015.08.025
   PubMed Web of Science ®Google Scholar
• Halpern R, Barghout V, Mody-Patel N, Williams D. Relationship between compliance, costs, hospitalizations for CML and GIST patients using imatinib mesylate. J Clin Oncol. 2008;26(15):6598. doi:10.1200/jco.2008.26.15_suppl.6598
   Web of Science ®Google Scholar
• Halpern R, Barghout V, Williams D. Compliance with imatinib mesylate associated with lower health resource utilization and costs for patients with CML and GIST. BLOOD. 2007;110(11):372B–372B. doi:10.1182/blood.V110.11.5159.5159
   Web of Science ®Google Scholar
• De Almeida MH, Pagnano K, Souza H, Souza CA. Adherence to Tyrosine Kinase Inhibitors (TKI) in Chronic Myeloid Leukemia (CML) seems to be related to duration of treatment and type. Haematologica. 2010;95:343.
   Web of Science ®Google Scholar
• Feng W, Henk H, Thomas S, et al. Compliance and persistency with imatinib. J Clin Oncol. 2006;24(18):310S–310S. doi:10.1200/jco.2006.24.18_suppl.6038
   Google Scholar
• Guerin A, Bollu V, Guo A, et al. Non-adherence to imatinib in Chronic Myeloid Leukemia (CML) patients is associated with short- and long-term negative impacts on health care resource utilization and costs. Value Health. 2010;13(3):A32–A32. doi:10.1016/S1098-3015(10)72137-9
   Web of Science ®Google Scholar
• StCharles M, Bollu VK, Hornyak E, Coombs J, Blanchette CM, DeAngelo DJ. Predictors of treatment non-adherence in patients treated with imatinib mesylate for chronic myeloid leukemia. Blood. 2009;114(22):870. doi:10.1182/blood.V114.22.2209.2209
   Web of Science ®Google Scholar
• Wu EQ, Guerin A, Yu AP, Bollu VK, Guo A, Griffin JD. Retrospective real-world comparison of medical visits, costs, and adherence between nilotinib and dasatinib in chronic myeloid leukemia. Curr Med Res Opin. 2010;26(12):2861–2869. doi:10.1185/03007995.2010.533648
   PubMed Web of Science ®Google Scholar
• Farmer AJ, Rodgers LR, Lonergan M, et al. Adherence to oral glucose-lowering therapies and associations with 1-year HbA(1c): a retrospective cohort analysis in a large primary care database. Diabetes Care. 2016;39(2):258–263. doi:10.2337/dc15-1194
   PubMed Web of Science ®Google Scholar
• Joensuu H. Risk stratification of patients diagnosed with gastrointestinal stromal tumor. Hum Pathol. 2008;39(10):1411–1419. doi:10.1016/j.humpath.2008.06.025
   PubMed Web of Science ®Google Scholar
• Chuah PL, Jamal NF, Siew CJ, Ahmad Bustamam RS, Jeyasingam V, Khong KC. Assessment of adherence to imatinib and health-related quality of life among patients with gastrointestinal stromal tumor: a cross-sectional study in an oncology clinic in Malaysia. Patient Prefer Adherence. 2021;15:2175–2184. doi:10.2147/PPA.S310409
   PubMed Web of Science ®Google Scholar
• Kao CC, Hsieh HM, Lee DY, Hsieh KP, Sheu SJ. Importance of medication adherence in treatment needed diabetic retinopathy. Sci Rep. 2021;11(1):19100. doi:10.1038/s41598-021-98488-6
   PubMed Web of Science ®Google Scholar
• Kucukarslan SN, Lewis NJ, Shimp LA, Gaither CA, Lane DC, Baumer AL. Exploring patient experiences with prescription medicines to identify unmet patient needs: implications for research and practice. Res Social Adm Pharm. 2012;8(4):321–332. doi:10.1016/j.sapharm.2011.08.003
   PubMed Web of Science ®Google Scholar
• Hyman DJ, Pavlik VN. Characteristics of patients with uncontrolled hypertension in the United States. N Engl J Med. 2001;345(7):479–486. doi:10.1056/NEJMoa010273
   PubMed Web of Science ®Google Scholar
• Tran C, Knowles SR, Liu BA, Shear NH. Gender differences in adverse drug reactions. J Clin Pharmacol. 1998;38(11):1003–1009. doi:10.1177/009127009803801103
   PubMed Web of Science ®Google Scholar
• Hurwitz N, Wade OL. Intensive hospital monitoring of adverse reactions to drugs. Br Med J. 1969;1(5643):531–536. doi:10.1136/bmj.1.5643.531
   PubMed Web of Science ®Google Scholar
• Böttiger LE. Adverse drug reaction: an analysis of 310 consecutive reports to the Swedish drug reaction committee. J Clin Pharmacol. 1973;13(10):373–382. doi:10.1002/j.1552-4604.1973.tb00182.x
   PubMed Web of Science ®Google Scholar
• Lucas C. The Arts Dying to survive and cancer care in China. Lancet Oncol. 2019;20(1):30. doi:10.1016/S1470-2045(18)30921-5
   PubMed Web of Science ®Google Scholar
• Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353(5):487–497. doi:10.1056/NEJMra050100
   PubMed Web of Science ®Google Scholar
• Sikka R, Xia F, Aubert RE. Estimating medication persistency using administrative claims data. Am J Manag Care. 2005;11(7):449–457.
   PubMed Web of Science ®Google Scholar
• Krapek K, King K, Warren SS, et al. Medication adherence and associated hemoglobin A(1c) in type 2 diabetes. Ann Pharmacother. 2004;38(9):1357–1362. doi:10.1345/aph.1D612
   PubMed Web of Science ®Google Scholar
• Blay JY, Rutkowski P. Adherence to imatinib therapy in patients with gastrointestinal stromal tumors. Cancer Treat Rev. 2014;40(2):242–247. doi:10.1016/j.ctrv.2013.07.005
   PubMed Web of Science ®Google Scholar
• Le Cesne A, Ray-Coquard I, Bui BN, et al. Discontinuation of imatinib in patients with advanced gastrointestinal stromal tumours after 3 years of treatment: an open-label multicentre randomised Phase 3 trial. Lancet Oncol. 2010;11(10):942–949. doi:10.1016/S1470-2045(10)70222-9
   PubMed Web of Science ®Google Scholar
• Saponara M, Pantaleo MA, Nannini M, Biasco G. Chronic therapy in gastrointestinal stromal tumours (GISTs): the big gap between theory and practice. Target Oncol. 2012;7(4):243–246. doi:10.1007/s11523-012-0221-1
   PubMed Web of Science ®Google Scholar
• Dirnhofer S, Leyvraz S. Current standards and progress in understanding and treatment of GIST. Swiss Med Wkly. 2009;139(7–8):90–102.
   PubMed Web of Science ®Google Scholar
• Hauber AB, Gonzalez JM, Coombs J, Sirulnik A, Palacios D, Scherzer N. Patient preferences for reducing toxicities of treatments for gastrointestinal stromal tumor (GIST). Patient Prefer Adherence. 2011;5:307–314. doi:10.2147/PPA.S20445
   PubMed Web of Science ®Google Scholar
• Hansen R, Seifeldin R, Noe L. Medication adherence in chronic disease: issues in posttransplant immunosuppression. Transplant Proc. 2007;39(5):1287–1300. doi:10.1016/j.transproceed.2007.02.074
   PubMed Web of Science ®Google Scholar
• Morisky DE, Ang A, Krousel-Wood M, Ward HJ. Predictive validity of a medication adherence measure in an outpatient setting. J Clin Hypertens. 2008;10(5):348–354. doi:10.1111/j.1751-7176.2008.07572.x
   PubMed Web of Science ®Google Scholar